ScreenerHero

RGNXREGENXBIO Inc.

NAS · US · Healthcare · Biotechnology · regenxbio.com
10.72USD-10.82%Mkt Cap: 707.66M $P/E: —

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Techn…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
REGENXBIO Q2 Earnings Call Highlights

REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic

MarketBeat
Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

Regenxbio advances RGX-202 and RGX-121 programs while securing $208 million in new funding to support operations through late 2027.

GuruFocus.com
Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
New Strong Sell Stocks for July 23rd

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

Zacks
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Zacks
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

REGENXBIO plans to sell $100 million worth of its common stock in an underwritten public offering.

Stocktwits
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
Zacks
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
Pharmaceutical Technology
Sector Update: Healthcare Stocks Rise Late Afternoon
MMT Newswires
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
Bloomberg
RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy
Stocktwits
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
BioPharma Dive
FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The Wall Street Journal
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
MMT Newswires
Are Options Traders Betting on a Big Move in REGENXBIO Stock?
Zacks
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Zacks
How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary
Simply Wall St.